Insiders Trades
Cigna Group Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Nov 2025.
Cigna Group: what insiders have been doing
Cigna Group, founded in 1982, is a Healthcare & Pharma company based in Bloomfield, United States. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 29 filings signed by 20 insiders.
The record shows 1 purchase on the open market worth €867k, made by 1 insider, against 2 sales worth €646k by 2 insiders. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Cordani David filed the largest purchase, €867k, on 3 November 2025. Those buying include 1 chief executive.
With 29 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Over the whole record (from 2023), the tally stands at 1 purchase and 13 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 274.90 bn USD and net income at 5.96 bn USD; the dividend was 6.04 USD per share.
The last purchase on record was published on 3 November 2025, which is 349 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
164
Thresholds
n/a
Buy Volume
€867,377
1 ops. · all time
Sell Volume
€10M
13 ops. · all time
Who traded when
BuySaleNicole S. Jones2 sales
Brian C. Evanko1 sale
David Cordani1 buy
Eder Noelle K1 sale
Jamie G. Kates1 sale
Neville Everett1 sale
Since the insiders bought
- +2.6%Entry US$264.66 · Close at T+90 US$271.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cigna Group Buy (bullish), based on 24 analysts. Average price target: US$342.29.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,883 of 24,148 companies
58.1
score / 100
Value75
Quality42
FCF yld11%
Earn yld7.5%
EV/EBITDA9.2x
ROE17%
Gross mgn9.0%
Net mgn2.2%
Debt/EBITDA2.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$298.81
Analyst consensus
24 analystsBuy
US$288.00Target US$342.29(+15%)US$400.00
Income statement
RevenueUS$273.9B
Gross profitUS$24.5B9% margin
EBITDAUS$12B4% margin
Net incomeUS$6B2.3% margin
Valuation
PER (trailing)12.4x
PER (forward)8.9x
P/Book1.8x
Beta0.30
Balance sheet & cash
Market capUS$79B
Total debtUS$31.5B
Free Cash FlowUS$8.4B
Debt / Equity74%
Profitability & ownership
ROE16.8%
ROA4.5%
% insiders1.4%
% institutions92.2%
Last declaration on 3 September 2026
Declarations164 total
617 shares@ US$284.050.0002% mcap5.8% of flowCommonSEC144:0001959173-26-006684
3,113 shares0Common Stock, $.01 Par ValueSEC:0001722909-26-000007:0
2,677 shares@ US$279.610.0010% mcap4.3% of flowCommon Stock, $.01 Par ValueSEC:0001492663-26-000003:0
2,677 shares@ US$279.57250.0010% mcap4.3% of flowCommonSEC144:0001959173-26-006144
14,045 shares@ US$192.020.0037% mcap15.5% of flowCommon Stock, $.01 Par ValueSEC:0001739940-26-000067:0
1,301 shares@ US$192.020.0003% mcap1.4% of flowCommon Stock, $.01 Par ValueSEC:0001739940-26-000067:2
19,436 shares@ US$276.270.0074% mcap30.9% of flowCommonSEC144:0001959173-26-005596
899 sharesCommon Stock, $.01 Par ValueSEC:0001739940-26-000047:1
899 sharesCommon Stock, $.01 Par ValueSEC:0001739940-26-000047:0
899 shares@ US$298.6120.0003% mcap100.0% of flowCommonSEC144:0001959173-26-004623
103,595 shares@ US$149.1350.017% mcap57.5% of flowCommon Stock, $.01 Par ValueSEC:0001739940-26-000044:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000028:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000029:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000030:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000031:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000033:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000034:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000036:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000037:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000032:0
782 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000035:0
205 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000018:0
2,602 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000016:0
4,133 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000014:0
499 shares0Common Stock, $.01 Par ValueSEC:0001739940-26-000017:0
25 of 164 declarations
About Cigna Group
The Cigna Group (NYSE: CI) is a U.S.-listed global health company headquartered in Bloomfield, Connecticut, United States. Its corporate roots go back to 1792, when the Insurance Company of North America was formed in Philadelphia; the modern company was built through decades of insurance and employee-benefits consolidation and now operates under the Cigna and Evernorth brands. For investors, the key takeaway is that Cigna is not a pure insurer: it combines health coverage with health services, giving it a more integrated model than many peers. The company says it serves customers in more than 30 countries and jurisdictions, underscoring its international reach despite its U.S.-centered earnings base. ([thecignagroup.com](https://www.thecignagroup.com/about-us/milestones?utm_source=openai))
The group’s operating structure is built around two main platforms: Cigna Healthcare and Evernorth Health Services. Cigna Healthcare provides health benefits and insurance solutions for U.S. employers, government programs, and international customers, with offerings spanning medical, dental, pharmacy, behavioral health, and care-navigation support. Evernorth is the health services engine of the group, focused on pharmacy benefit management, specialty and care services, and other capabilities designed to improve affordability, access, and clinical outcomes. This combination is strategically important because it allows The Cigna Group to participate both in risk-bearing insurance and in fee-based or service-oriented healthcare infrastructure, which can support resilience across different cycles. ([thecignagroup.com](https://www.thecignagroup.com/es-us/about-us/?utm_source=openai))
Read moreShow less
Cigna’s product set is broad and practical rather than consumer-glitzy: employer medical plans, dental coverage, pharmacy administration, behavioral health access, virtual care, and digital tools that help members understand benefits and costs. In 2025, the company highlighted new AI-powered digital capabilities and launched Clearity by Cigna Healthcare, a copay-only health plan designed to make pricing more transparent and the customer experience more predictable. That emphasis on simplicity and transparency is a recurring theme in recent company communications and reflects management’s effort to improve member experience while defending competitive positioning. ([newsroom.cigna.com](https://newsroom.cigna.com/cigna-healthcare-unveils-industry-leading-ai-powered-digital-tools?utm_source=openai))
From a market-position standpoint, The Cigna Group is one of the major U.S. health-benefits and health-services franchises. Its scale, national provider relationships, and integration across insurance and services are meaningful competitive advantages, especially in employer-sponsored health and pharmacy-related services. At the same time, earnings sensitivity to medical trend remains a key analytical issue: the company’s 2024 results showed continued strength in Evernorth, while Cigna Healthcare was affected by higher stop-loss medical costs. Management also disclosed the planned divestiture of the Medicare businesses to HCSC, expected to close in the first quarter of 2025, which is relevant for understanding portfolio reshaping and future earnings mix. In March 2026, the company announced a new Chief Medical Officer for Cigna Healthcare, signaling continued investment in clinical leadership and care delivery. ([investors.thecignagroup.com](https://investors.thecignagroup.com/files/doc_earnings/2024/q4/earnings-result/the-cigna-group-fourth-quarter-2024-release.pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
